{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:08:25Z","timestamp":1785776905698,"version":"3.56.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>A subset of patients with chronic myelomonocytic leukemia (CMML) presents with significance myelofibrosis. In myelodysplastic syndromes, significant myelofibrosis has been associated with adverse outcomes and p53 dysregulation. However, in CMML the clinical and molecular correlates of significant myelofibrosis at presentation remain poorly understood. From a cohort of 651 CMML patients, we identified retrospectively 20 (3.1%) cases with moderate to severe reticulin fibrosis (CMML-F) detected at diagnosis, and we compared them to CMML patients without fibrosis (n=631) seen during the same period. Patients with CMML-F had a median age of 69.8 years (range, 24.8 to 91.2\u2009y) and most (13; 65%) were men. Patients with CMML-F differed significantly from other CMML patients across the following parameters: white blood count, absolute monocyte count, serum lactate dehydrogenase level, splenomegaly, and bone marrow blast percentage. Notably, the frequency of <jats:italic toggle=\"yes\">JAK2<\/jats:italic> p.V617F mutation was higher in CMML-F patients compared with other CMML patients (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Most CMML-F patients (12\/20; 60%) had myeloproliferative CMML. Dysregulation of p53 was uncommon in CMML-F. CMML-F patients tended to have a shorter median overall survival compared with other CMML patients (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.079). Multivariate analysis using the Cox proportional hazards model showed an independent association between CMML-F and overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.047). In summary, unlike typical CMML, CMML-F is commonly associated with <jats:italic toggle=\"yes\">JAK2<\/jats:italic> p.V617F. The high frequency of myeloproliferative features and <jats:italic toggle=\"yes\">JAK2<\/jats:italic> p.V617F mutation, and the low frequency of p53 dysregulation, suggest that fibrosis in the context of CMML has a different pathogenesis from that previously reported in myelodysplastic syndrome.<\/jats:p>","DOI":"10.1097\/pas.0000000000001058","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T04:11:45Z","timestamp":1522296705000},"page":"799-806","source":"Crossref","is-referenced-by-count":39,"title":["Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations"],"prefix":"10.1097","volume":"42","author":[{"given":"Hatice D.","family":"Gur","sequence":"first","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Routbort","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Quesada","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Khogeer","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Hematopathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia","volume":"153","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-015-0271-4","article-title":"Chronic myelomonocytic leukemia: a genetic and clinical update","volume":"10","author":"McCullough","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"57021","DOI":"10.18632\/oncotarget.10937","article-title":"Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features","volume":"7","author":"Palomo","year":"2016","journal-title":"Oncotarget"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2015-0094","article-title":"Fibrogenesis in primary myelofibrosis: diagnostic, clinical, and therapeutic implications","volume":"20","author":"Nazha","year":"2015","journal-title":"Oncologist"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.13529","article-title":"TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis","volume":"171","author":"Loghavi","year":"2015","journal-title":"Br J Haematol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"30492","DOI":"10.18632\/oncotarget.9026","article-title":"Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis","volume":"7","author":"Ramos","year":"2016","journal-title":"Oncotarget"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jcp.2009.065904","article-title":"JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia","volume":"62","author":"Pich","year":"2009","journal-title":"J Clin Pathol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00277-013-1945-4","article-title":"Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis","volume":"93","author":"Machherndl-Spandl","year":"2014","journal-title":"Ann Hematol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R20-20230922","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/modpathol.2017.148","article-title":"Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia","volume":"31","author":"Chapman","year":"2017","journal-title":"Mod Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","article-title":"Validation of immunohistochemical assays for integral biomarkers in the NCI-MATCH EAY131 clinical trial","volume":"24","author":"Khoury","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/S0046-8177(03)00412-X","article-title":"Cytogenetic findings in blastoid mantle cell lymphoma","volume":"34","author":"Khoury","year":"2003","journal-title":"Hum Pathol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3324\/haematol.2013.093765","article-title":"Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring","volume":"99","author":"Luthra","year":"2014","journal-title":"Haematologica"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.23652","article-title":"BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS","volume":"89","author":"Zhang","year":"2014","journal-title":"Am J Hematol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PAS.0b013e3182712481","article-title":"Phospho-ERK(THR202\/Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections","volume":"37","author":"Warden","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.30383","article-title":"Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1309\/FU04P779U310R3EE","article-title":"Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease","volume":"126","author":"Wang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:35:32Z","timestamp":1695422132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201806000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001058","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}